Noven Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved Stavzor™ (valproic acid delayed release capsules) in 125 mg, 250 mg and 500 mg strengths. Stavzor is approved for the treatment of manic episodes associated with bipolar disorder, as monotherapy and adjunctive therapy in the treatment of patients with complex partial seizures that occur either in isolation or in association with other types of seizures, and for prophylaxis of migraine headaches. The product will be marketed and sold by Noven Therapeutics, LLC, Noven’s specialty pharmaceutical subsidiary, and is expected to be available in pharmacies in the second half of August.
The details can be read here.
No comments:
Post a Comment